Status:
RECRUITING
Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Healthy
Eligibility:
All Genders
25+ years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to determine whether equivalent moderately high doses of LSD, psilocybin, and DMT produce qualitatively similar peak effects when the effect duration is standard...
Detailed Description
Lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT) are serotonergic hallucinogens (psychedelics) and currently investigated as therapeutic tools for the treatment of variou...
Eligibility Criteria
Inclusion
- Good understanding of the German language
- Understanding of procedures and risks associated with the study
- Willing to adhere to the protocol and signing of the consent form
- Willing to refrain from the consumption of illicit psychoactive substances during the study
- Willing not to operate heavy machinery within 48 h after administration of a study substance
- Willing to use effective birth control throughout study participation
- Body mass index 17 - 34.9 kg/m2
Exclusion
- Relevant chronic or acute medical condition
- Current or previous major psychiatric disorder (e.g. psychotic disorder)
- Psychotic disorder or bipolar disorder in first-degree relatives
- Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg)
- Bradycardia (\< 45 bpm)
- Prolonged QTc interval (males: \>450 ms, females: \>470 ms)
- AV block II° (Mobitz type and Webckebach type) and III°
- Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months
- Pregnancy or current breastfeeding
- Participation in another clinical trial (currently or within the last 30 days)
- Use of medication that may interfere with the effects of the study medication
- Tobacco smoking (\>10 cigarettes/day)
- Excessive consumption of alcoholic beverages (\>15 drinks/week)
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06899334
Start Date
April 1 2025
End Date
August 1 2026
Last Update
March 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Basel, Switzerland, 4056